Bracco Launches AI Imaging Platform in EU

Why it matters

The AiMIFY® platform, co-developed with U.S.-based Subtle Medical, Inc., utilizes deep learning algorithms to enhance contrast in brain MRI images. The software can amplify the contrast enhancement to double the level achieved with a standard dose of gadolinium-based contrast agents (GBCAs). This technological leap aims to improve diagnostic confidence by increasing the visibility of small or poorly enhanced brain lesions without altering established imaging protocols. The platform received FDA clearance in the United States in October 2024 and the European CE Mark in June 2025, paving the way for this commercial launch. The move positions Bracco, a global leader in diagnostic imaging with €1.7 billion in annual revenue, deeper into the rapidly growing

Key numbers

• The platform received FDA clearance in the United States in October 2024 and the European CE Mark in June 2025, paving the way for this commercial launch.
• The move positions Bracco, a global leader in diagnostic imaging with €1.7 billion in annual revenue, deeper into the rapidly growing

What happens next

• This technological leap aims to improve diagnostic confidence by increasing the visibility of small or poorly enhanced brain lesions without altering established imaging protocols.
• The platform received FDA clearance in the United States in October 2024 and the European CE Mark in June 2025, paving the way for this commercial launch.
• The move positions Bracco, a global leader in diagnostic imaging with €1.7 billion in annual revenue, deeper into the rapidly growing Diagnostic imaging firm Bracco announced the EU launch of its AI platform, AiMIFY®, at the European Congress of Radiology.

Sources

• Bracco announced
• The AiMIFY® platform
• The software can amplify
• This technological leap

Quick answers